Follicular Thyroid Carcinoma; A cell-mediated approach to sFlt-1 gene therapy targets thyroid cancer
Posted on: Thursday, 4 March 2004, 06:00 CST
2004 MAR 12 - (NewsRx.com & NewsRx.net) -- A cell-mediated approach to sFlt-1 gene therapy targets thyroid cancer.
According to recent research from the United States, "tumor progression largely depends on blood supply and neovessel formation, and angiogenesis is emerging as a promising target for cancer therapy. Vascular endothelial growth factor (VEGF), a major proangiogenic molecule, stimulates angiogenesis via promoting endothelial proliferation, survival and migration. VEGF has been found to be up-regulated in various types of tumors and to be associated with tumor progression and poor prognosis."
"Inhibition of VEGF or its signaling pathway has been shown to suppress tumor angiogenesis and tumor growth. In the present study, we tested the antiangiogenic and antitumor effects of soluble VEGF receptor-1 [soluble Flt (sFlt)-1] on the growth of follicular thyroid carcinoma (FTC). We constructed a 293 embryonic kidney cell line (293-Flt1- 3d) that expresses sFlt- 1, which is composed of the first three extracellular domains of Flt-1," wrote C.S. Ye and colleagues, University of Pittsburgh, Institute of Cancer.
"The 293-Flt1-3d cells inhibited the in vitro growth of human umbilical vein endothelial cells in a paracrine manner."
"The in vivo antitumor and antiangiogenic activities of the 293- Flt1-3d cells were tested. When 293-Flt1-3d cells were inoculated at a site remote to the FTC-133 tumor transplant, the growth of FTC- 133 tumors were inhibited by 70.37%, as compared with the control treatment with 293 cells expressing control gene LacZ. Immunohistochemical analysis of microvessel densities in treated tumors demonstrated that 293-Flt1-3d cells robustly suppressed intratumoral angiogenesis," Ye and coauthors reported.
"Our data suggest that a mammalian cell-mediated approach could effectively deliver sFlt-1 gene therapy and inhibit tumor angiogenesis and tumor growth," they concluded.
Ye and colleagues published their study in Endocrinology (sFlt-1 gene therapy of follicular thyroid carcinoma. Endocrinology, 2004;145(2):817-822).
For additional information, contact M.F. Li, University Pittsburgh, Institute Cancer, Hill Cancer Center Research Pavil, 5117 Center Avenue, Suite G12-G, Pittsburgh, PA 15213, USA.
Publisher contact information for the journal Endocrinology is: Endocrine Society, 4350 East West Highway Suite 500, Bethesda, MD 20814-4110, USA.
The information in this article comes under the major subject areas of Angiogenesis, Biotechnology, Endocrinology, Oncology, Cancer Therapy, and Thyroid Cancer.
This article was prepared by Drug Week editors from staff and other reports. Copyright 2004, Drug Week via NewsRx.com & NewsRx.net.
Related Articles
- Clinical Center of Serbia, Institute for Cardiovascular Diseases Treats First Patient in Trial of Pioneering Stem Cell-Derived Therapy for Heart Failure
- Leading Experts Endorse Bioheart's Muscle Stem Cell MyoCell Therapy
- Noninvasive Imaging of Cell-Mediated Therapy for Treatment of Cancer
- MethylGene Initiates Phase I Clinical Trial for Its Multi-Targeted (C-Met) Kinase Inhibitor, MGCD265, in Solid Tumor Cancers
- Clinical Data on Vidaza(R) (Azacitidine for Injectable Suspension) in Various Hematologic and Solid Tumor Cancers Presented at the American Society of Clinical Oncology 42nd Annual Meeting
- ZIOPHARM Announces Interim Results in ZIO-101 Phase I Solid Tumor Cancer Trial; Clinical Activity in Several Cancers
- PhereSys Therapeutics Announces Consulting Agreement With Advanced Cell & Gene Therapy, LLC
- Breast Cancer Uses Growth Factors to Lure Stem Cells
- Stem Cell-Based Therapy Enters Clinical Trials
- Vertex and Merck Announce First Clinical Study for Aurora Kinase Inhibitor, VX-680, in Solid Tumor Cancers
 |
 |
User Comments (0)
RSS Feeds